Increased nuclear accumulation of β-catenin, a mediator of canonical Wnt signaling, is found in numerous tumors and is frequently associated with tumor progression and metastasis. Inhibition of Wnt/β-catenin signaling therefore is an attractive strategy for anticancer drugs. In this study, we have identified a novel small molecule inhibitor of the β-catenin signaling pathway, JW55, that functions via inhibition of the PARP domain of tankyrase 1 and tankyrase 2 (TNKS1/2), regulators of the β-catenin destruction complex. Inhibition of TNKS1/2 poly(ADP-ribosyl)ation activity by JW55 led to stabilization of AXIN2, a member of the β-catenin destruction complex, followed by increased degradation of β-catenin. In a dose-dependent manner, JW55 inhibited canonical Wnt signaling in colon carcinoma cells that contained mutations in either the APC (adenomatous polyposis coli) locus or in an allele of β-catenin. In addition, JW55 reduced XWnt8-induced axis duplication in Xenopus embryos and tamoxifen-induced polyposis formation in conditional APC mutant mice. Together, our findings provide a novel chemotype for targeting canonical Wnt/β-catenin signaling through inhibiting the PARP domain of TNKS1/2. Cancer Res; 72(11); 2822–32. ©2012 AACR.
The Wnt/β-catenin signaling pathway is a key regulator in numerous cellular processes including stem cell maintenance, fate decision, and cell-cycle control (1, 2). The main denominator of canonical Wnt signaling, β-catenin, has several cellular functions. At the cell membrane, it is associated with E-cadherin and participates in the formation of the adherens junctions (3). In the cytoplasm, β-catenin can form complexes with a multitude of proteins, including the β-catenin destruction complex consisting of adenomatous polyposis coli (APC), AXIN2, GSK3β, and CK1α (4, 5). Tankyrase 1 and 2 (TNKS1/2) regulate the stability of the β-catenin destruction complex through AXIN2 by poly(ADP-ribosyl)ation (6). Although TNKS1/2 modulates the destruction complex, this complex interferes with TNKS. Evidence suggests that TNKS is phosphorylated in a cell-cycle–dependent manner by GSK3β (7). TNKS is furthermore controlled by the ubiquitin E3 ligase RNF146 that destabilizes TNKS1/2, AXIN2, and itself by ubiquitinylation (8, 9). In the standard model, the destruction complex regulates the sequential phosphorylation of β-catenin by the kinases CK1α at S45 and by GSK3β at S33, S37, and T41. This leads to polyubiquitination by β-TrCP and subsequent degradation of β-catenin by the proteasome (10, 11). Active Wnt signaling inhibits the function of the destruction complex, and β-catenin is not phosphorylated at the N-terminus and degraded, but enters the nucleus. Nuclear uptake of β-catenin may be further enhanced by the context-dependent C-terminal phosphorylation of β-catenin at S675, leading to increased nuclear translocation (12). In addition to canonical Wnt signaling, a variety of alternative cellular mechanisms may trigger altered nuclear accumulation of β-catenin. These mechanisms include the Hif-1a signaling pathway, downregulation of E-cadherin or C-terminal phosphorylation of β-catenin through HGF-activated cMet (13–15). Furthermore, PKA-involving mechanisms can lead to C-terminal phosphorylation of β-catenin and enhance its nuclear presence (12). Recently it was discovered that the primary cilium diverts Jouberin from the nucleus and limits β-catenin nuclear entry (16).
In the nucleus, β-catenin exerts a number of functions, such as binding to the transcription factor TCF/LEF by replacing Groucho and activation of downstream transcription of genes, including c-Myc, Cyclin D1, and AXIN2 (2). Nuclear β-catenin levels are not only determined by the rate of β-catenin import to the nucleus but also by “nuclear trapping” of β-catenin through factors such as TCF/LEF (17).
In general, mutations in genes encoding central components of the Wnt/β-catenin pathway and the destruction complex lead to the accumulation of nuclear β-catenin and contribute to tumor initiation and progression (18, 19). Wnt activating mutations are found in a broad range of solid tumors including colon cancer, gastric cancer, hepatocellular carcinoma, breast cancer, medulloblastoma, melanoma, non–small cell lung cancer, pancreas adenocarcinoma, and prostate cancer (20). It has been well established that the majority of intestinal neoplasia with deregulated Wnt signaling harbor truncating mutations in both alleles of the APC tumor suppressor gene (21).
Considerable efforts have been made to identify drugs that inhibit Wnt/β-catenin signaling (18, 22–25). Published inhibitory drugs that interact with biotargets directly associated with canonical Wnt signaling include WAY-316606 for SFRP (26), niclosamide for frizzled (27), NCS668036 for Dsh (28), pyrvinium for CK1 (24), XAV939 and IWR-1 for TNKS1/2 (4, 22), 2,4-diamino-quinazoline, quercetin, PKF115-584 and ICG-001 for β-catenin and its binding to TCF or CREB (29–32).
TNKS1/2, in particular, is a promising biotarget for pharmaceutical reagents (4, 6). TNKS1/2 is not only involved in controlling canonical Wnt signaling but has been associated with further cellular processes through either protein poly(ADP-ribosyl)ation (PARsylation) or by protein complex formation. These are (i) telomere maintenance by interacting with TRF1 (33), (ii) spindle formation and stabilization by binding to NuMA (33), and (iii) glucose metabolism by regulating GLUT4 transport through IRAP (33).
In this work, we have identified a novel TNKS inhibitor, JW55, which inhibits the PARP domain of TNKS1/2, leading to the stabilization of AXIN2 followed by increased degradation of β-catenin. JW55 efficiently decreases canonical Wnt signaling in colon carcinoma cell lines, in a Xenopus axis duplication assay, and in tamoxifen-induced tumors in ApcCKO/CKOLgr5-CreERT2+ mice. The identified chemotype JW55 may serve as an attractive start point for the development of novel cancer therapeutics.
Materials and Methods
Cell lines and luciferase assays
All cell lines were purchased from American Type Culture Collection and maintained and treated according to the supplier's recommendations. Reporter assays were carried out as previously described (34).
IncuCyte cell growth measurement assay
A total of 1,000 SW480 or RKO cells were seeded in 96-well plates. The day after, the cell culture medium was exchanged to solutions that contained 0.1% dimethyl sulfoxide (DMSO) or 10 μmol/L JW55 for RKO cells and 0.1% DMSO or 10, 5, or 1 μmol/L JW55 for SW480 cells. All samples consisted of a minimum of 6 replicates. The plate was incubated in an IncuCyte (Essen BioScience) inside a cell culture incubator. Images were captured every second hour to monitor proliferation.
A total of 400 SW480, RKO, or HeLa cells were seeded in 6-cm plates and 1% FBS. The day after, the medium was exchanged to 0.05% DMSO or 5 μmol/L JW55 for RKO and HeLa cells, and 0.1% DMSO or 5, 1, or 0.1 μmol/L JW55 for SW480 cells (minimum 3 replicates). The cells were grown until colonies appeared in the control plates and medium was changed twice a week. The plates were stained and fixed with 0.2% methylene blue in methanol and washed with PBS. The colonies were counted manually with a colony counter (Scienceware). Representative pictures of colonies were captured with a Leica MZ Apo Stereomicroscope connected to a Leica DC200 camera and Adobe Photoshop.
Tumor initiation and treatment in ApcCKO/CKO/Lgr5-CreERT2 mice
Seven 12-week old female ApcCKO/CKO/Lgr5-CreERT2 mice were injected intraperitonally with 25 mg/kg of tamoxifen (Sigma) diluted in an ethanol and corn oil (ratio 1:4). The mice were randomized into 2 groups and treated with either JW55 (100 mg/kg) or vehicle (DMSO). Daily per oral applications started the day after and continued for 3 weeks. The mouse body weight was measured twice a week. The mice were sacrificed and the intestines were dissected, washed in PBS, and fixed in formaldehyde [10% solution (v/v) in PBS]. The small intestines were stained using 1% methylene blue prepared in 10% paraformalaldehyde (PFA)/PBS solution. Small ileum Swiss-rolls were embedded in paraffin sectioned and stained with hematoxylin and eosin (H&E). Fixed colons were embedded in paraffin, sectioned and stained with an anti–β-catenin antibody (610153; BD Transduction Laboratories; see Supplementary Materials and Methods for further details). The number and size of the intestinal lesions were quantified by the Ellipse program (ViDiTo).
For other materials and methods, please see previous descriptions (34) and Supplementary Materials and Methods.
JW55 is a potent and selective inhibitor of the canonical Wnt pathway
To identify chemical compounds that inhibit the canonical Wnt signaling pathway, a library consisting of 37,000 small molecules (ChemBioNet) was screened using HEK293 cells that were stably transfected with a SuperTOP-d1EGFP reporter (34). The vector contains a synthetic TCF-responsive promoter (SuperTOP: 7 x TCF binding sites) that initiates the expression of destabilized d1EGFP upon activation of canonical Wnt signaling (34). Canonical Wnt signaling was activated using conditioned media (CM) from L Wnt3a expressing cells. The screen resulted in 77 primary hits including the previously described compounds JW67 and JW74 (34) and JW55 (Fig. 1A, right panel). To evaluate the efficacy and specificity of JW55, the compound was tested in 3 different luciferase reporter assays. Wnt3a-induced HEK293 cells containing a transiently transfected ST-Luc (SuperTop-luciferase) reporter showed inhibition by JW55 with an IC50 value of 470 nmol/L (Fig. 1A, left panel and Supplementary Fig. S1A). In contrast, Shh Light II cells (Gli1-Luc reporter) that were activated with 50% Shh-CM were not inhibited by 10 or 1 μmol/L JW55. Also, TNFα−activated HEK293 cells containing a transiently transfected NF-κB–Luciferase (NF-κB-Luc) plasmid showed no pathway inhibition in the presence of 10 or 1 μmol/L of JW55 (Fig. 1B and C).
The selectivity and specificity of JW55 was further tested in an in vivo Xenopus axis duplication assay, a highly stringent test for examining inhibitors of canonical Wnt signaling. When injected into the ventral blastomeres of 4-cell stage Xenopus laevis embryos, XWnt8 mRNA induced Wnt signaling resulting in the formation of a second body axis. By using selective Wnt inhibitors, the axis duplication can be inhibited and a normal phenotype restored (34). Coinjection of 10 pg XWnt8 and 2 pmol of JW55 resulted in a significant 51% reduction of the axis duplication incidence in developing frog embryos when compared with the DMSO vehicle control (z-test, P = 0.001; Fig. 1D, left). This result provided evidence that JW55 acts as a specific and effective inhibitor of canonical Wnt signaling.
JW55 regulates β-catenin stability at the level of the destruction complex
To identify the interference point of JW55 with canonical Wnt signaling, the effect of JW55 was monitored after LiCl-induced activation of the pathway. The activity of GSK3β, which is part of the β-catenin destruction complex, is reduced in the presence of LiCl (35), rendering the N-terminal phosphorylation of β-catenin by GSK3β ineffective. This causes nuclear accumulation of β-catenin and active Wnt signaling. HEK293 cells, transiently transfected with ST-Luc and Renilla, were incubated with 25 mmol/L LiCl and different doses of JW55. The LiCl-activating effect was counteracted by JW55 in a dose-dependent manner with an IC50 value of 360 nmol/L, indicating that JW55 acts at the level or downstream of the destruction complex (Fig. 2A, left and Supplementary Fig. S1B).
Next, the effect of JW55 on regulating the activity of β-catenin was tested. We used (i) wild-type β-catenin and (ii) β-catenin with point mutations in the N-terminal phosphorylation sites (S33, S37, T41, and S45) that resists degradation and functions as dominant active (da-Cat). Plasmids containing full-length β-catenin or da-Cat, along with ST-Luc and Renilla, were transiently transfected in HEK293 cells. The expression of wild-type β-catenin led to an increased ST-Luc reporter activity that could be reduced by 55% when the transfected cells were exposed to 10 μmol/L of JW55 (normality test failed, rank sum test: P = 0.001; Fig. 2A, right). In contrast, the activation of the pathway by da-Cat could not be inhibited by 10 μmol/L JW55, further indicating that JW55 acts at the level or downstream of the destruction complex (normality test failed, rank sum test: P = 0.457; Fig. 2A, right).
JW55 inhibits canonical Wnt signaling in colorectal cancer cell lines in vitro
Mutations in the APC gene, which occur in nearly all colorectal cancers (CRC; ref. 18), lead to ineffective degradation of β-catenin and aberrant upregulation of Wnt signaling. The cell lines SW480 and HCT-15 (mutated in codon 1338 and 1417 of the APC gene, respectively) were stably transfected with ST-Luc and Renilla and incubated at various doses of JW55 for 48 hours. A dose-dependent reduction of luciferase activity was detected in both cell lines. JW55 was effective in the range of 1 to 5 μmol/L in SW480 cells and 0.01 to 5 μmol/L in HCT-15 cells (Fig. 2B, left). Next, HCT116 CRC cells with integrated ST-Luc and Renilla reporters were used to test JW55. HCT116 carries a point mutation in the CK1α-dependent phosphorylation site S45 of one β-catenin allele; however, S45-mutated β-catenin may still be phosphorylated in the remaining GSK3β phosphorylation sites (e.g. S33, S37, and T41), with resulting semiregulated β-catenin turnover (36). In HCT116 cells, JW55 was effective in the range of 0.01 to 5 μmol/L (Fig. 2B, right). A basal luciferase expression level at approximately 50% was reached after exposure to 5 μmol/L in the CRC cells.
Furthermore, the effect of JW55 on the expression of endogenous Wnt target genes was examined by real-time PCR in the cell lines SW480 and DLD-1. Compared with SW480 cells, the APC mutation in DLD-1 cells results in a more extensive C-terminal deletion (37). In SW480 cells, a dose-dependent decline in the expression of the 3 target genes was observed: AXIN2 (25 μmol/L: 55% and 10 μmol/L: 45%), SP5 (25 μmol/L: 38% and 10 μmol/L: 15%) and NKD1 (25 μmol/L: 31% and 10 μmol/L: 7%; Fig. 2C, left). A similar reduction was observed in DLD-1 cells after exposure to 10 μmol/L of JW55 (AXIN2: 72%, SP5: 38% and NKD1: 66%; Fig. 2C, right). Subsequently, a more extensive Illumina gene expression analysis was carried out in JW55-treated SW480 cells. Several Wnt target genes (Wnt homepage) were differently expressed (Supplementary Table S1). Upregulated genes included (Log2 ≥ 0.5): WISP3, TCF7, PLAUR, EFNB2, and NOTUM. Downregulated genes included (Log2 ≤ −0.5): AXIN2, NKD1, DKK1, MMP7, ID2, GAST, FZD2, EDN1, CYR61, SOX18 and, similar to our previous observations (34), members of the SPANX gene family.
JW55 destabilizes β-catenin by increasing cytoplasmic AXIN2 levels
Previous studies have shown that an increase in AXIN2 steady-state levels induced by TNKS1/2 or CK1a inhibitors is accompanied by a decrease in β-catenin concentrations (4, 22, 24, 34). Increased levels of AXIN2 protein promote degradation of β-catenin even in cells with truncated APC (4, 22, 38). Western blot analysis of SW480 cells lysates revealed a dose-dependent increase of cytoplasmic AXIN2 after JW55 treatment (range: 10 μmol/L–100 nmol/L; Fig. 3A and Supplementary Fig. S2). Furthermore, an antibody against the active and nonphosphorylated form of β-catenin (active β-catenin, ABC) identified reduced levels of β-catenin in the cytoplasm of JW55-treated cells (Fig. 3A and Supplementary Fig. S2). In addition, a modest reduction of total β-catenin and a substantial decrease of nuclear ABC were observed, and an increase in phosphorylated β-catenin (pβ-catenin) levels was seen indicating ongoing β-catenin degradation (Fig. 3A and Supplementary Fig. S2).
To gain further insight into the changes in cellular distribution of AXIN2 and β-catenin, JW55-treated SW480 cells were analyzed by immunofluorescence. A general reduction of total β-catenin, both in the cytoplasmic and nuclear compartments, was detected at the doses of 5 and 1 μmol/L (equal shutter speed; Supplementary Fig. S3). Confocal microscopy (equal shutter speeds) revealed, in accordance with the Western blot analysis, that the levels of cytoplasmic AXIN2 were significantly increased (Fig. 3B) and large protein foci, probably representing accumulated destruction complexes, were observed (Fig. 3B, arrows). Clusters of colocalized cytoplasmic β-catenin and AXIN2 have previously been detected in SW480 cells after treatment with the Wnt antagonist JW74 (34). Similar to JW74, enhanced phosphorylation and resulting degradation of β-catenin after JW55 exposure seemed to be orchestrated by stabilization of AXIN2 in the destruction complex (Fig. 3 and 5).
JW55 specifically inhibits the PARsylation activity of TNKS1 and TNKS2
By inhibiting the PARP domain of TNKS1/2, XAV939, IWR-1, and JW74 prevent auto-PARsylation of TNKS1/2 and PARsylation of AXIN2 (4, 22, 39, 40). This leads to a stabilization of AXIN2, an accumulation of proteins in the destruction complex followed ultimately by an increased degradation of β-catenin (4, 22). To test whether JW55 decreased canonical Wnt signaling by directly inhibiting the PARP domain of TNKS1/2, we carried out biochemical assays for monitoring the activity of TNKS1/2 and PARP. JW55 decreased auto-PARsylation of TNKS1/2 in vitro with IC50 values of 1.9 μmol/L and 830 nmol/L, respectively (Fig. 4A and Supplementary Fig. S1C). However, in contrast to XAV939 (ref. 4; Fig. 4A and Supplementary Fig. S1D), but similar to IWR-1 (4), JW55 exhibited no inhibition of PARP1 at doses up to 20 μmol/L (Fig. 4A). Although further details may emerge, present evidence suggests that JW55 decreases canonical Wnt signaling by specifically inhibiting the PARP domain of TNKS1/2 (Fig. 5), although leaving the activity of the PARP domain of at least PARP1 unaffected. Molecular docking of JW55 into the adenosine site of the human PARP domain of TNKS2 using the structure of the PARP domain in complex with IWR-1 (X-ray, PDB code 3UA9) reveals that the binding site and position of JW55 in the model is similar to IWR-1 (40), but different from XAV939 (Supplementary Fig. S4). Binding of JW55 to recombinant TNKS2 protein was also observed by using a fluorescence polarization competition assay, with a structurally similar but inactive analog as a negative control (ref. 41; Supplementary Fig. S5). Interestingly, opposite to the effect of XAV939 (4), a decrease in endogenous TNKS1/2 levels was detected after exposure to JW55 and IWR-1 in SW480 cells.
JW55 reduces growth of SW480 colon cancer cells
CRC cells can enter cell-cycle arrest as a result of antagonized canonical Wnt signaling (42–44). Various proliferation assays were carried out to see whether JW55-mediated inhibition of canonical Wnt signaling would affect CRC cell growth. First, SW480 cells were incubated with 10 μmol/L JW55 and labeled with bromodeoxyuridine (BrdUrd) and propidium iodide (PI). The subsequent flow cytometry cell-cycle analysis revealed that JW55 treatment lowered the proportion of cells in the S phase (from 28.4% in DMSO-treated controls to 22.2%), raised moderately the cell fraction in the G1 phase (from 37.3%–38.8%) and increased the number of cells in G2–M phase (from 34.3%–39%; Fig. 6A).
Next, we monitored the cell proliferation kinetics using IncuCyte. SW480 cells were exposed to 10, 5, or 1 μmol/L of JW55 for 9 days, and the confluency was measured every 2 hours. All doses of JW55 reduced SW480 cell growth and the most robust effect was detected at a dose of 10 μmol/L JW55. The confluency was reduced to 55% relative to the DMSO control at the end of experiment (Fig. 6B). In parallel, the CRC cell line RKO, which contains wild-type APC and β-catenin and exerts Wnt-independent cell growth, was used as a control. RKO cells reached 100% confluency within 7 days and were not affected by treatment with 10 μmol/L JW55 (Fig. 6B).
Furthermore, proliferation of SW480 cells was examined by consecutive passages in the presence of 5, 2.5, or 1 μmol/L JW55. A dose-dependent decrease of cell numbers over 3 passages was noted in SW480 cells in the presence of JW55, whereas HeLa cells (Wnt-independent cervical cancer cells) remained unaffected (Fig. 6C). Finally, SW480 cells were grown under low serum conditions (1% FBS) along with various concentrations of JW55 (5, 1, and 0.1 μmol/L) and the formation of colonies was quantified. We observed a concentration-dependent reduction of colony numbers in SW480 cells and no reduction in colony numbers in the control cell lines HeLa and RKO when cultured in 5 μmol/L JW55 (Fig. 6D, left). All SW480 colonies, which formed in the presence of JW55, were substantially smaller (Fig. 6D, right).
Taken together, these data showed that JW55-mediated inhibition of canonical Wnt signaling resulted in reduced cell-cycle progression, proliferation, and colony formation in the CRC cell line SW480 in vitro.
JW55 reduces tumor development in conditional Apc knockout mice
Recently, the leucine-rich repeat containing G-protein–coupled receptor 5 (Lgr5) was established as a specific marker for intestinal epithelium stem cells (ISC). The knockin mouse Lgr5-EGFP-IRES-CreERT2, further referred to as Lgr5-CreERT2, expresses a tamoxifen-regulated variant of Cre recombinase that is under the control of the Lgr5 locus (45). The Cre-mediated excision of the floxed exon 14 in mice with conditional Apc alleles (CKO) changes the reading frame downstream of the deletion. This results in the production of a truncated and nonfunctional 580 amino acid (aa) Apc polypeptide (46) that relates to the homozygous mutations seen in the intestinal cancer model mouse ApcMin (multiple intestinal neoplasia, Min; ref. 47). Lgr5-CreERT2 mice were intercrossed with ApcCKO/CKO animals and multiple tumors were observed after tamoxifen injections in the small intestine (ileum) and the colon of ApcCKO/CKOLgr5-CreERT2+ mice (Fig. 7A and Supplementary Fig S6). In the colon, fewer tumors developed when compared with the general adenoma progress in the small intestine. To evaluate the JW55-mediated decrease of intestinal tumor development in vivo, ApcCKO/CKOLgr5-CreERT2+ mice were injected intraperitoneally with a 25 mg/kg single dose of tamoxifen. A day after, daily per oral applications of JW55 (100 mg/kg; 3 females) or vehicle (DMSO; 4 females) were initiated. The dose of 100 mg/kg was chosen to counteract the rapid liver metabolism of JW55 as indicated by the human liver microsome stability analysis (t½ = 10.1 minutes; Supplementary Fig. S7A). No measurable effects on mouse body weight were noticed throughout the experiment period (Supplementary Fig. S7B). After 21 days, the mice were sacrificed and the dissected intestines were embedded in paraffin and sectioned. Immunohistochemical staining revealed that the neoplastic lesions expressed β-catenin and the mouse ISC marker Ephrin type-B receptor 2 (EphB2), indicating aberrant activation of canonical Wnt signaling in the tumor tissue (Fig. 7B; refs. 44, 48–50). The β-catenin–stained colon adenomas contrasted with the surrounding healthy mucosa, and image analysis software (Ellipse) was used to quantify the number and areas of β-catenin–positive lesions in the colon (Supplementary Fig. S7C). As it was impossible to distinguish the borders of individual tumors in the small intestine (ileum), only the total tumor area per mouse was recorded. In the ileum, a significant reduction of the total tumor area was observed after JW55 injections (mean: 2.93 mm2 and median: 2.95 mm2) when compared with the control group (mean: 8.84 mm2 and median: 9.51 mm2; normality test failed, rank sum test: P = 0.003; Fig. 7A and C, top panel). In the colon, the tumor count was substantially reduced in JW55-treated mice (mean: 9.7 and median: 6.0) when evaluated against the control group (mean: 33.8 and median: 26.0; normality test failed, rank sum test: P = 0.057; Fig. 7C, bottom panel). Furthermore, a significant decrease of the total tumor area was noticed after injections with JW55 (mean: 0.022 mm2) when compared with the control group (mean: 0.154 mm2; Students t test: P = 0.009; Fig. 7C, bottom panel). The area of single tumors was significantly reduced after injections with JW55 (mean: 0.0025 mm2) when compared with the untreated group (mean: 0.0049 mm2; Students t test: P = 0.043; Fig. 7C, bottom panel). Interestingly, the proportion of cells that expressed Ki67, a marker of proliferating and ISC-like cells (50), was substantially decreased in adenomas exposed to JW55 when compared with tumors that developed in the control mice (Fig. 7B, panel h and i).
Importantly, when examining the healthy mucosa with antibodies against various epithelial cell populations, such as EphB2 for ISCs and Krt20 for terminally differentiated epithelial cells (50), we did not observe changes in its morphology, proliferation, or differentiation after exposure to JW55 (Fig. 7D). In summary, the results obtained from JW55-treated conditional Apc knockout mice indicated that in vivo small-molecular inhibition of TNKS1/2 leads to decreased canonical Wnt signaling followed by reduced adenoma induction and possibly progression of adenoma carcinoma.
Altered properties of Wnt/β-catenin signaling are enabling factors for a multitude of diseases, including cancer. Among known interference points in the canonical Wnt signaling pathway, the PARP domains of TNKS1/2 seem to be a particular suitable target for inhibiting the pathway. Blocking the PARP domain of TNKS1/2 with low molecular inhibitors, such as XAV939, IWR-1, and JW74 (4, 34), leads to the stabilization of the destruction complex that triggers increased degradation of β-catenin (19). As predicted for a TNKS inhibitor, we observed a massive cytoplasmic accumulation of AXIN2 after treatment with 500 nmol/L JW55, followed by a significant reduction of β-catenin levels in vitro (Fig. 5). A similar stabilization of AXIN2 was also seen with JW74, XAV939, and IWR-1 (4, 22, 34). However, despite the substantial increased specificity of JW55 to the PARP domain of TNKS1/2 when compared with XAV939, we cannot rule out that JW55 may affect additional mechanisms that contribute to the observed effects in colon cancer cell lines and in ApcCKO/CKOLgr5-CreERT2+ mice. For instance pyrvinium decreases Wnt signaling both by stabilizing AXIN2 and through inhibition of CK1α (24). Furthermore, in complementation to altering canonical Wnt/β-catenin signaling, a JW55-mediated inhibition of TNKS1/2 may induce additional intracellular effects including altered telomere maintenance or spindle formation.
The in vivo treatment of tamoxifen-induced polyposis in ApcCKO/CKOLgr5-CreERT2+ mice JW55 showed a profound effect on tumor progression. In comparison with the well-established ApcMin mice (47), this mouse model provides a clearer assay for scoring adenoma formation because the tumor induction and treatment are time controlled. However, as adenoma induction is rather strong, it is difficult to assess later stages of CRC development as mouse mortality does not allow long-term tracking of the tumors. Thus, the presented data further solidify the functional implication of PARsylation by TNKS1/2 in a malignant transformation of the colon and the small intestine.
Interestingly, in our setting, the exposure of progenitor cells in a normal crypt to JW55 did not exert visible alterations in the intact mucosa as measured with the markers EphB2, Ki67, and Krt20. However, we cannot exclude that a longer treatment may cause reduction in cell turnover in the intestine epithelium (45). The efficient in vivo reduction of adenomas in mice and CRC growth in vitro by a tankyrase-specific inhibitor further strengthens the importance of TNKS and β-catenin as potential therapeutic biotargets.
TNKS1/2 is a member of a family of 5 PARP proteins in humans, including PARP1, which is an extensively explored target for drug development (33). Particularly in the BRCA1/2 mutant background, PARP1 inhibitors exhibit therapeutic effects in vitro and in vivo. Because PARP proteins are involved in a range of biologic functions, including genome maintenance, the selectivity of PARP inhibitors may be an issue in the therapeutic setting. Similar to XAV939, JW55 inhibits auto-PARsylation of TNKS1 and TNKS2 in a biochemical assay. However, in contrast to XAV939, we see no evidence for the inhibition of PARP1 by JW55, making this chemotype attractive for further development toward a TNKS1/2 selective inhibitor. It remains to be determined in which settings a preferred PARP1 inhibitor such as for instance olaparib, a broad PARP inhibitor such as XAV939, or a selective TNKS inhibitor such as JW55, JW74, and IWR-1 may be the favorable choice.
Disclosure of Potential Conflicts of Interest
The described chemical compound may have commercial value if further investigated.
J. Waaler, O. Machon, O. Machonova, H. Dinh, and S. Krauss were supported by the Research Council of Norway, CRI program, and Helse Sør-Øst, grant 2010031; O. Machon and O. Machonova were supported by grant Agency of the Czech Republic (GACR P305/12/2042); L. Tumova and V. Korinek were supported by qChIP/chip06 project from the Ministry of Education, Youth and Sports of the Czech Republic (B06077), and the institutional grant from the Academy of Sciences of the Czech Republic (AV0Z50520514).
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
The authors thank R. Kemler for da-Cat plasmid, R. Moon for ST-Luc plasmid, and C. Erdmann for helping with the high-throughput screen as well as A. Philimonenko for help with the image evaluation using the Ellipse software.
Note: Supplementary data for this article are available at Cancer Research Online (http://cancerres.aacrjournals.org/).
- Received October 13, 2011.
- Revision received February 15, 2012.
- Accepted March 7, 2012.
- ©2012 American Association for Cancer Research.